EUVIMEDEUVIMED entdecken
Leserbrief

Persistence of a High Seroconversion Rate 3.2 ± 0.13 Years After Last COVID‐19 Vaccination in Heart Transplant Recipients

Robin Arcani, Pierre Ambrosi iD

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70190 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Robin Arcani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Therapeutics and the Aix-Marseille Universite, Marseille, France. Hauptthemen laut MEDLINE: Antibodies, Viral, COVID-19, COVID-19 Vaccines, Heart Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously reported a high level of seroconversion 1 year after COVID‐19 vaccination in heart transplant recipients when vaccination was performed several years after transplantation. The aim of this study was to measure the seroconversion rate late after vaccination, in the absence of a new vaccine injection. We included 37 patients vaccinated in 2021. We measured immunoglobulin response using TrimericS Diasorin assay at the last visit between October 2024 and February 2025. We found a seroconversion rate of 95%, 3.2 ± 0.13 years after last COVID‐19 vaccination in the absence of new vaccine injection. Most of these patients (73%) had a proven COVID‐19 infection since vaccination. Interestingly, none of these patients had a severe form of COVID‐19. Thus, vaccination, followed by minor COVID‐19 infections, effectively prevented severe forms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralCOVID-19COVID-19 VaccinesHeart TransplantationSARS-CoV-2SeroconversionTransplant RecipientsAdultAgedFemaleHumansMaleMiddle AgedFollow-Up StudiesVaccination

Stichwörter der Autor:innen

COVID‐19heart transplantationvaccination

Substanzen

Antibodies, ViralCOVID-19 Vaccines

Autor:innen und Institutionen

  • Laboratory of Therapeutics and the Aix-Marseille Universite, Marseille, France.
  • Cardiac Transplant Unit, La Timone Hospital, Aix-Marseille University, Marseille, France.

ORCID-Profile: Pierre Ambrosi

Zitieren

APA

Arcani, R., & Ambrosi, P. (2025). Persistence of a High Seroconversion Rate 3.2 ± 0.13 Years After Last COVID‐19 Vaccination in Heart Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70190

Vancouver

Arcani R, Ambrosi P. Persistence of a High Seroconversion Rate 3.2 ± 0.13 Years After Last COVID‐19 Vaccination in Heart Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70190

BibTeX
@article{Arcani2025,
  author = {Arcani, Robin and Ambrosi, Pierre},
  title = {Persistence of a High Seroconversion Rate 3.2 ± 0.13 Years After Last COVID‐19 Vaccination in Heart Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70190}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche